Pfizer Ends Sangamo Alliance With Gene Therapy for Hemophilia on Cusp of FDA Filing
Posted:
Pfizer is walking away from partner Sangamo Therapeutics ahead of expected regulatory submissions for the hemophilia A gene therapy they co-developed. Cash-strapped Sangamo said it is now looking for a new partner for the program.
Read the full article in the latest MedCity News blog post here.
Discover how Finland’s leading health technology hub is advancing digital healthcare through collaboration, research and innovation
The future of healthcare is being shaped by collaboration between researchers, technology pioneers, healthcare providers and businesses. In Oulu, Finland, this collaboration has created…
From AI-powered healthcare platforms to virtual hospitals, Abto Software is advancing the future of digital health
Healthcare is undergoing a rapid transformation, with technology playing a vital role in improving access to care, supporting clinicians, and enabling more personalised patient…